Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $3.2 million.

  • OptimizeRx's Free Cash Flow rose 8648.81% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 123473.17%. This contributed to the annual value of $4.6 million for FY2024, which is 15671.73% up from last year.
  • As of Q3 2025, OptimizeRx's Free Cash Flow stood at $3.2 million, which was up 8648.81% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Free Cash Flow ranged from a high of $4.5 million in Q2 2025 and a low of -$5.5 million during Q4 2023
  • For the 5-year period, OptimizeRx's Free Cash Flow averaged around $995546.9, with its median value being $742000.0 (2024).
  • As far as peak fluctuations go, OptimizeRx's Free Cash Flow tumbled by 94935.28% in 2023, and later skyrocketed by 450256.41% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Free Cash Flow stood at -$1.6 million in 2021, then soared by 265.3% to $2.7 million in 2022, then plummeted by 302.66% to -$5.5 million in 2023, then surged by 101.73% to $95000.0 in 2024, then skyrocketed by 3270.53% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $4.5 million for Q2 2025, and $3.8 million during Q1 2025.